J B Chemicals & Pharmaceuticals Ltd

J B Chemicals & Pharmaceuticals Ltd

Next 500 2024
+ 9 More
+ 9 More
OVERVIEW
FINANCIALS

About

Established in 1976, JB Chemicals and Pharmaceuticals is one of India's fastest-growing pharmaceutical companies. With a diverse portfolio spanning gastroenterology, dermatology, nephrology, respiratory, virology, diabetes, and Nicotine Replacement Therapy, they focus on delivering patient-friendly formulations. Beyond India, their key markets include Russia and South Africa, with exports to over 30 countries, including the USA. JBCPL is a global leader in medicated lozenges, ranking among the top five manufacturers worldwide. Their seven state-of-the-art manufacturing facilities, including a dedicated lozenge plant, are certified by major global regulators. Over the years, they have expanded through strategic acquisitions, collaborations, and regulatory approvals, strengthening their R&D and market presence. With a commitment to innovation and excellence, JB Chemicals and Pharmaceuticals continues to grow as a trusted pharmaceutical brand worldwide.

Incorporation Year: 1976
Headquarters: Mumbai, Maharashtra
Top Management: Nikhil Chopra (CEO)
Industry: Pharma
Website: jbpharma.com

Featured In Fortune India Ranking

#465(2021)
Next 500 India
#38(2024)#33(2023)#14(2021)#96(2020)#115(2019)#125(2018)#128(2017)#164(2016)#265(2015)
#38(2024)#33(2023)#14(2021)#96(2020)#115(2019)#125(2018)#128(2017)#164(2016)#265(2015)
Ranking Trend Fortune Next 500 India

Financial Data 2024

Revenue
3,568
(INR Cr)
Net Operating Income
3,484
(INR Cr)
Assets
3,321
(INR Cr)
Profit
553
(INR Cr)
Net Worth
2,923
(INR Cr)

Financial Data

RevenueNet Operating IncomeProfitAssetsNet Worth
PARAMETERS2024202320222021202020192018201720162015201420132012201120102009
Revenue
(INR Cr)
3568
12.6%
3170
27.8%
2481
13.0%
2196
20.1%
1829
7.4%
1704
17.3%
1452
4.8%
1386
8.1%
1282
9.4%
1171
8.6%
1078
20.8%
893
-43.4%
1578
72.4%
916
18.9%
770
4.4%
737
-
Net Operating Income
(INR Cr)
3484
10.63%
3149
29.91%
2424
18.69%
2043
15.09%
1775
8.00%
1643
16.67%
1408
4.77%
1344
11.07%
1210
5.78%
1144
11.97%
1022
17.98%
866
8.02%
802
-9.98%
891
20.54%
739
3.34%
715
27.71%
Profit
(INR Cr)
553
34.8%
410
6.4%
385
-14.0%
448
64.7%
272
40.6%
193
39.9%
138
-24.8%
184
13.2%
163
61.9%
100
63.3%
62
-22.6%
79
-88.3%
678
386.6%
139
17.3%
119
361.9%
26
-
Assets
(INR Cr)
3321
8.2%
3071
38.9%
2210
17.8%
1876
26.6%
1482
-2.3%
1517
2.0%
1487
3.9%
1431
2.7%
1393
22.8%
1134
-1.2%
1148
6.5%
1079
2.8%
1049
20.8%
868
23.2%
705
8.8%
648
-
Net Worth
(INR Cr)
2923
17.9%
2480
16.2%
2134
17.9%
1810
26.1%
1435
-3.0%
1480
2.7%
1442
5.7%
1364
15.2%
1184
19.0%
995
-4.6%
1043
3.3%
1010
5.2%
960
40.5%
684
21.3%
564
20.7%
467
4.4%
Employee Cost
(INR Cr)
601
10.7%
543
23.7%
439
29.0%
341
5.5%
323
12.1%
288
14.8%
251
15.5%
217
24.0%
175
9.9%
160
11.1%
144
10.5%
130
15.4%
113
-9.8%
125
18.7%
105
7.4%
98
-
Interest Cost
(INR Cr)
44365735351176424101215
Cash & Bank Balance
(INR Cr)
96795931313730131325121562201277844
Total Debt
(INR Cr)
378572554529262949193127935071169137179

Key Financial Ratios

Profit As % Of RevenuesRONW %Interest Cost to EBITDA %ROCE %Debt to Equity Ratio
PARAMETERS2024202320222021202020192018201720162015201420132012201120102009
Profit As % Of Revenues 15.5%12.9%15.5%20.4%14.9%11.4%9.5%13.3%12.7%8.6%5.7%8.9%43.0%15.2%15.4%3.5%
Profit As % Of Assets 16.6%13.4%17.4%23.9%18.4%12.8%9.3%12.9%11.7%8.9%5.4%7.4%64.6%16.1%16.9%4.0%
Profit As % Of Networth 18.9%16.5%18.1%24.8%19.0%13.1%9.6%13.5%13.7%10.1%5.9%7.9%70.6%20.4%21.1%5.5%
Interest Cost to EBITDA % 4.9%5.2%0.9%1.3%0.8%1.5%1.6%2.3%5.2%3.8%7.1%3.8%24.0%5.5%7.7%26.7%
Debt to Equity Ratio 0.130.230.030.020.020.020.020.040.160.130.090.050.070.250.240.38
RONW 20.5%17.8%19.6%24.8%18.7%13.3%7.6%11.8%12.6%9.9%8.6%6.4%8.1%22.3%23.0%5.6%
ROCE 24.9%22.4%25.0%32.3%23.5%19.5%10.5%13.4%15.0%13.4%12.6%8.0%11.1%22.5%23.7%8.1%